| Project/Area Number |
25670412
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Kidney internal medicine
|
|---|
| Research Institution | Kochi University |
|---|
Principal Investigator |
TERADA Yoshio 高知大学, 教育研究部医療学系, 教授 (30251531)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | オートファジー / 尿細管 / 急性腎障害 / 虚血 / 慢性腎臓病 / 再生医学 / 腎臓 / マイトファジー |
|---|
| Outline of Final Research Achievements |
We deal with the assessment of the protective role of 5-aminolevulinic acid (ALA) in cisplatin-induced acute kidney injury (AKI). Nephrotoxicity is a frequent and major limitation of cisplatin-based chemotherapy. ALA is widely distributed in animal cells and is a precursor of tetrapyrole compounds such as heme, which is fundamentally important in aerobic energy metabolism. We found 2 novel findings: First, ALA ameliorates renal function in cisplatin-induced AKI by protecting mitochondrial enzymes and viability, as well as prevents tubular apoptosis in vivo and in vitro. Second, ALA has no significant effects on the anticancer efficiency of cisplatin in rats. Thus, ALA has the potential to prevent cisplatin-induced nephrotoxicity without compromising the anticancer efficacy of cisplatin.
|
